Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
599 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J, Wong MG, Hladunewich MA, et al. · JAMA · 2022Multicenter Study, Randomized Controlled Trial
- A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Lafayette R, Barbour S, Israni R, et al. · Kidney Int · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
Perkovic V, Barratt J, Rovin B, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Atrasentan in Patients with IgA Nephropathy.
Heerspink HJL, Jardine M, Kohan DE, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Wheeler DC, Toto RD, Stefánsson BV, et al. · Kidney Int · 2021Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, et al. · Lancet · 2023Randomized Controlled Trial, Multicenter Study
- Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Perkovic V, Trimarchi H, Tesar V, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Iptacopan in IgA Nephropathy - Final 24-Month Data.
Barratt J, Eren N, Kashihara N, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.
Lafayette R, Barbour SJ, Brenner RM, et al. · N Engl J Med · 2026Randomized Controlled Trial, Multicenter Study
- Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, et al. · Lancet · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Epidemiology of IgA Nephropathy: A Global Perspective.
Schena FP, Nistor I · Semin Nephrol · 2018Research Support, Non-U.S. Gov't, Systematic Review
- A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.
Lafayette RA, Canetta PA, Rovin BH, et al. · J Am Soc Nephrol · 2017Randomized Controlled Trial
- A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M, Barratt J, Chacko B, et al. · N Engl J Med · 2024Randomized Controlled Trial, Multicenter Study
- Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ, Reid S, Craig JC, et al. · Cochrane Database Syst Rev · 2024Meta-Analysis, Systematic Review
- Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
Neuen BL, Perkovic V, Agarwal R, et al. · JAMA · 2026Randomized Controlled Trial, Multicenter Study
- Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Lv J, Liu L, Wang W, et al. · N Engl J Med · 2026Randomized Controlled Trial, Multicenter Study
- Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy.
Floege J, Lafayette R, Barratt J, et al. · Kidney Int · 2025Clinical Trial, Phase II, Randomized Controlled Trial
- Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H, Rizk DV, Perkovic V, et al. · Kidney Int · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Heerspink HJL, Jardine MJ, Kohan DE, et al. · Lancet · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.
Chen B, Zhu Y, Yang Y, et al. · Front Med (Lausanne) · 2025Systematic Review
- Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review.
Xu L, Wu C, Li G · J Nephrol · 2025Systematic Review
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
Rauen T, Eitner F, Fitzner C, et al. · N Engl J Med · 2015Multicenter Study, Randomized Controlled Trial
- The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.
McGrogan A, Franssen CF, de Vries CS · Nephrol Dial Transplant · 2011Editorial, Research Support, Non-U.S. Gov't
- Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC, Barratt J, Cook H, et al. · Lancet · 2017Clinical Trial, Phase II, Randomized Controlled Trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.